Journal
BONE MARROW TRANSPLANTATION
Volume 51, Issue 5, Pages 645-653Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2015.349
Keywords
-
Categories
Funding
- Grants-in-Aid for Scientific Research [15K09513] Funding Source: KAKEN
Ask authors/readers for more resources
Although allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor (MSD) is a potentially curative post-remission treatment for adults with acute myeloid leukemia (AML) in their first CR, transplant-related morbidity and mortality remains a major drawback. We retrospectively compared the outcomes of patients who underwent autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 375) with those who underwent allogeneic bone marrow transplantation (allo-BMT; n = 521) and allo-PBSCT (n = 380) from MSDs for adults with AML/CR1, in which propensity score models were used to adjust selection biases among patients, primary physicians and institutions to overcome ambiguity in the patients' background information. Both the multivariate analysis and propensity score models indicated that the leukemia-free survival rate of auto-PBSCT was not significantly different from that of allo-BMT (hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.92 to 1.66; P = 0.16) and allo-PBSCT (HR, 1.13; 95% CI, 0.85-1.51; P = 0.40). The current results suggest that auto-PBSCT remains a promising alternative treatment for patients with AML/CR1 in the absence of an available MSD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available